| 0.32 0 (0%) | 11-15 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Stealth BioTherapeutics Corp is a clinical-stage biotechnology firm dedicated to discovering, developing, and bringing to market treatments for illnesses arising from mitochondrial dysfunction. Its primary therapeutic candidate, Elamipretide, is currently progressing through multiple clinical stages: a Phase 3 trial for Barth Syndrome and replisome myopathies; a Phase 2/3 study for Duchenne cardiomyopathy; a Phase 2a investigation for Friedreich's ataxia; and Phase 2 trials for both dry age-related macular degeneration and Leber's hereditary optic neuropathy. The company's developmental pipeline further includes SBT-20, designed to address complications associated with diabetes, various renal and ocular conditions, and several neurodegenerative diseases such as Parkinson's, Alzheimer's, Huntington's, and ALS. Additionally, SBT-550 is being evaluated for rare neurological indications, while SBT-272, a peptidomimetic, is engineered to target and enhance mitochondrial function amidst oxidative stress. Established in 2006, Stealth BioTherapeutics Corp operates from its base in George Town, Cayman Islands.
Wed, 16 Nov 2022
Stealth BioTherapeutics Corp Announces Completion of Merger - PR Newswire
Mon, 01 Aug 2022
Stealth BioTherapeutics Corp Enters Definitive Agreement for Going Private Transaction - PR Newswire
Mon, 11 Apr 2022
Stealth BioTherapeutics Announces $8.5 Million in Equity Financings - PR Newswire
Tue, 16 Mar 2021
Stealth BioTherapeutics Announces Promotion of Marty Redmon to Chief Research & Development Officer - BioSpace
Mon, 13 Apr 2020
Stealth Biotherapeutics Announces $20 Million Financing to Advance Development of Elamipretide and Pipeline - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|